Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nasuh C Buyukkaramikli

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 9, 2020
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in EnglandNasuh C Buyukkaramikli, Peter Wigfield, Men Thi Hoang
Pharmacoeconomics|May 29, 2019
Severity-Adjusted Probability of Being Cost EffectiveMatthijs M Versteegh, Isaac Corro Ramos, Nasuh C Buyukkaramikli, et al.
Vaccines|November 25, 2023
Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"Maarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, et al.
Vaccines|May 27, 2023
Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in BelgiumMaarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 9, 2020
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in EnglandNasuh C Buyukkaramikli, Peter Wigfield, Men Thi Hoang
Pharmacoeconomics|May 29, 2019
Severity-Adjusted Probability of Being Cost EffectiveMatthijs M Versteegh, Isaac Corro Ramos, Nasuh C Buyukkaramikli, et al.
Vaccines|November 25, 2023
Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"Maarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, et al.
Vaccines|May 27, 2023
Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in BelgiumMaarten J Postma, Chih-Yuan Cheng, Nasuh C Buyukkaramikli, et al.
Pageof 1